December 18, 2024

Percheron Announces Termination of Phase 2B Study of Avicursen for Duchenne

PPMD is disappointed to learn of Percheron Therapeutics’ recent decision to terminate the company’s ongoing Phase 2b randomized, placebo-controlled trial of avicursen (ATL1102) in non-ambulatory individuals living with Duchenne following the release of topline six-month…

Learn More

November 25, 2020

Antisense Therapeutics: Introduction to the Duchenne Community

PPMD is thrilled to welcome Antisense Therapeutics to the Duchenne community. Antisense is developing a new potential therapy, ATL1102, using an antisense oligonucleotide (ASO) inhibitor aimed at treating muscle inflammation and associated muscle wasting. Although…

Learn More

October 26, 2020

Antisense Therapeutics Receives US FDA Orphan Drug Designation for ATL1102 for the Treatment of Duchenne

Antisense Therapeutics announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to the ATL1102 for treatment of Duchenne muscular dystrophy. ATL1102 is an antisense drug aimed at reducing…

Learn More

June 19, 2020

WATCH: Antisense Therapeutics Phase II Trial Final Data Results – Webinar Recording

Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into…

Learn More

September 25, 2019

Antisense Therapeutics Announces Positive Preliminary Results from ATL1102 for Duchenne Phase II Trial

Antisense Therapeutics has announced that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of the company’s immunomodulatory therapy, ATL1102…

Learn More